Moncef Slaoui, Ph.D., attracted both acclaim and controversy during his time as co-leader of the U.S. government’s Operation Warp Speed effort to speed COVID-19 vacc...

As AbbVie braces for biosimilar competition to its top drug Humira, the company is taking biosims maker Alvotech to task in court over alleged tr...

Johnson & Johnson's COVID-19 vaccine rollout has been more of a trickle than a stream so far in the U.S., with the company still on the hook to deliver some 15 m...

Magic Mountain has nothing on the ups and downs of AstraZeneca’s COVID-19 vaccine.  The latest? An AstraZeneca press release yesterday touting its U.S. vaccin...

Even as COVID-19 vaccines roll out across the globe, promising to eventually spark herd immunity to the virus, Regeneron’s executives have been preaching the value o...

PD-1/L1 inhibitors have had a relatively low success rate against cancers that affect the digestive system. But Merck & Co. can now tout a first-in-cla...

AstraZeneca’s COVID-19 vaccine rollout has hit one pothole after another—supply shortfalls, reports of blood clots and countries suspending usage, one by one. And ...

About a month before Pfizer and BioNTech won an emergency nod for their COVID-19 vaccine in Europe, regulators raised flags about lower-than-expected levels&nbs...

Specialty drugmaker ANI Pharmaceuticals has been steadily growing its generics arsenal over the past decade while also striving to expand its CDMO business. Now...

Last week, Viatris laid out its first financial targets for the new company, which combined generics specialist Mylan and Pfizer’s established medicines unit Upjohn....